Key contacts

Peter Molloy

Peter Molloy
Founding Director

Simon Bindloss

Simon Bindloss
Business Development Manager

Regional office - North America
245 Park Avenue
39th Floor
New York, NY 10167
Tel: +1 646 653 7026

listed companies

TransAtlantic Petroleum Afferro Mining
South American Silver Corp Infinity Pharmaceuticals
Exelixis Idenix
Pharmacyclics Ariad Pharmaceuticals
Arrowhead Research Corporation AVEO Pharmaceuticals
Sangamo BioSciences TransDigm Group
Array BioPharma Alnylam Pharmaceuticals
Spirit AeroSystems FLIR Systems
BioCryst Pharmaceuticals BioLineRx
Sucampo Pharmaceuticals Anthera Pharmaceuticals
See more

Companies with HQs in usa

Veris Gold Corp Nordgold
Ardea Biosciences CAE
Woulfe Mining RGI International
Altius Minerals Orbite Aluminae
Pan American Goldfields Nordion
Paladin Labs Dalradian Resources
Patheon Exact Sciences
MethylGene OPMEDIC Group
Torex Gold Canada Lithium Corporation
Xplore Technologies Corp Edgewater Exploration
See more

Latest research

OTC Markets Group

Growing market recognition

Update | Financials | 10/03/2017

Against a soft trading background OTC Markets Group (OTCM) delivered FY16 numbers slightly ahead of our expectation and the prior year. While the number of companies on its premium exchanges fell during the year there has been encouraging pick-up in new joiners in Q4 and early 2017. On a medium-term view the increased number of states, now 20, that grant OTCM markets Blue Sky recognition is important in helping draw in additional, good quality, corporate clients.

Orosur Mining

Production stable, exploration ramp up over H2

Update | Mining | 30/01/2017

Following a successful completion to mining at Arenal Deeps, Orosur has now transitioned most of its production to SGW UG. With ore mining now ramping up at SGW, we expect Orosur to meet its guidance mid-range at 37.5koz for FY17 at cash costs of between US$800/oz and US$900/oz. We also take a first-pass indicative value on its Anzá project, which we consider could grow materially and change the investment case for Orosur. Even on the basis of its announced exploration ‘target’…

Tonix Pharmaceuticals

Breakthrough Therapy Designation in PTSD

Update | Pharmaceutical & healthcare | 23/01/2017

Tonix has announced that it has been granted Breakthrough Therapy Designation (BTD) by the FDA as its Phase II AtEase data for TNX-102 SL in military-related PTSD indicate the drug may successfully treat a serious condition, a key requirement for BTD. Key benefits of BTD are intensive guidance from the FDA on the drug development program, an organizational commitment involving senior managers at the FDA, and the submission of portions of the NDA on a rolling basis.

Atossa Genetics

IDMC-fulvestrant trial site change, new timelines

Flash note | Pharmaceutical & healthcare | 11/01/2017

Atossa announced this week that it is transferring the site of its ongoing 30-pt Phase II study on intraductal catheter (IDMC) administered fulvestrant to the Montefiore Medical Center in New York City, from the Columbia University Medical Center where it had been initiated in March 2016. This move follows the relocation of the study’s primary investigator, Dr Sheldon M Feldman, from Columbia to Montefiore. Atossa believes this move will hasten patient recruitment, which it acknowledges had…

Euromax Resources

Maximising Europe

Update | Mining | 10/01/2017

Ilovica-Shtuka is a large project (ultimately it will account for 1-2% of Macedonian GDP) in a poor area of Europe with high unemployment. Now that parliamentary elections are completed, the stage is set for Euromax to raise equity and for the government to grant final construction permits early in CY17.

Edison North America

Edison’s North American office opened in 2011 to provide research services to companies listed on North American stock exchanges. Companies of all sizes benefit from our research service, which provides the highest standards of equity research and unrivalled distribution of our reports on a global and unrestricted basis.